← Return to Tymlos treatment plan - 18 months vs 24

Discussion
jasperina avatar

Tymlos treatment plan - 18 months vs 24

Osteoporosis & Bone Health | Last Active: May 1 5:01pm | Replies (20)

Comment receiving replies
Profile picture for gently @gently

mint, https://pmc.ncbi.nlm.nih.gov/articles/PMC6422956/
There is a subset of individuals who continue to maintain coupled bone markers longer than 24 months. Most of the studies are just to 18 months where you see at somewhere approaching 18 month there is this increase in CTX without the accompanying P1NP. If you are wondering about staying on Tymlos longer than 18 months, it is best to have you bone markers tested. There are doctors prescribing longer terms of treatment with both Forteo and Tymlos. I'm starting my fourth year of Forteo, checking serum bone markers every three months.
Research isn't telling us yet why the balance changes. Maybe resource depletion. We don't even know it the shift is transient. And if a person were to continue the medication after the decline we don't know if it would rise again. The pth drugs have my favored mechanism, so I'd like to remain on Forteo or Tymlos and avoid all the others.

Jump to this post


Replies to "mint, https://pmc.ncbi.nlm.nih.gov/articles/PMC6422956/ There is a subset of individuals who continue to maintain coupled bone markers longer..."

@gently Thank you for the information. That's very interesting.
I did find a research article on the effectiveness of treatment up to 24 months.
In case anyone is interested, the title is "Teriparatide for osteoporosis: importance of the full course" https://pmc.ncbi.nlm.nih.gov/articles/PMC4947115/
The conclusion is: "Both the biochemical and histological data suggest ongoing bone formation through 24 months, resulting in increases in bone mass, even in patients with low bone turnover induced by long-term previous anti-resorptive treatment. Consistent with these observations, bone mass and strength increase and fracture risk decreases during longer treatment with the drug."